Literature DB >> 17976692

Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature.

Concepción Moll1, M Victoria Hernández, Juan D Cañete, José A Gómez-Puerta, Alex Soriano, Antonio Collado, Raimon Sanmartí.   

Abstract

OBJECTIVE: To analyze the clinical efficacy of anti-tumor necrosis factor (TNF)-alpha therapy in the SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome. We describe 2 new cases with ilium osteitis as the main SAPHO syndrome feature and review reported cases treated with anti-TNF-alpha.
METHODS: A literature search of SAPHO syndrome cases treated with TNF-alpha blocking therapy with special emphasis on osteoarticular and skin responses was performed.
RESULTS: Eighteen cases were identified: 17 SAPHO syndrome and 1 chronic recurrent multifocal osteomyelitis, a juvenile variant of SAPHO syndrome. Sixteen were reported cases and 2 were nonreported cases seen in our arthritis unit. Sixteen patients received infliximab and 2 received etanercept, with an early, sustained clinical improvement in most cases.
CONCLUSIONS: Anti-TNF-alpha therapies are effective treatment for patients with refractory SAPHO syndrome, not only for cutaneous lesions but also for persistent bone lesions such as osteitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17976692     DOI: 10.1016/j.semarthrit.2007.08.004

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  15 in total

1.  The SAPHO syndrome: a clinical and imaging study.

Authors:  Meritxell Sallés; Alejandro Olivé; Ricard Perez-Andres; Susana Holgado; Lourdes Mateo; Elena Riera; Xavier Tena
Journal:  Clin Rheumatol       Date:  2010-09-28       Impact factor: 2.980

Review 2.  SAPHO Syndrome: Current Developments and Approaches to Clinical Treatment.

Authors:  Davide Firinu; Vanessa Garcia-Larsen; Paolo Emilio Manconi; Stefano R Del Giacco
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

3.  The lobster sign in SAPHO syndrome: unusually extensive osteitis of the anterior chest wall partially responsive to infliximab.

Authors:  Branimir Anić; Ivan Padjen; Marko Barešić; Stanko Težak
Journal:  Rheumatol Int       Date:  2012-12-22       Impact factor: 2.631

4.  Successful treatment of SAPHO syndrome with adalimumab: a case report.

Authors:  Ivan Castellví; Maria Bonet; Jose A Narváez; Jose C Molina-Hinojosa
Journal:  Clin Rheumatol       Date:  2010-05-06       Impact factor: 2.980

Review 5.  The SAPHO syndrome revisited with an emphasis on spinal manifestations.

Authors:  Antonio Leone; Victor N Cassar-Pullicino; Roberto Casale; Nicola Magarelli; Alessia Semprini; Cesare Colosimo
Journal:  Skeletal Radiol       Date:  2014-10-21       Impact factor: 2.199

6.  Response to infliximab in SAPHO syndrome.

Authors:  Julia Fruehauf; Brigitte Cierny-Modrè; Laila El-Shabrawi Caelen; Thomas Schwarz; Roland Weinke; Elisabeth Aberer
Journal:  BMJ Case Rep       Date:  2009-05-20

7.  [Successful therapy of sacroiliitis in SAPHO syndrome by etanercept].

Authors:  Carola Wolber; Karin David-Jelinek; Astrid Udvardi; Gottfried Artacker; Beatrix Volc-Platzer; Herbert Kurz
Journal:  Wien Med Wochenschr       Date:  2011-01-25

8.  SAPHO syndrome with bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer.

Authors:  Katsuhiko Matsumaru; Kazuki Nagai; Takayuki Murakami; Kazuo Andoh
Journal:  BMJ Case Rep       Date:  2010-08-31

Review 9.  Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment.

Authors:  Francesco Cianci; Angelo Zoli; Elisa Gremese; Gianfranco Ferraccioli
Journal:  Clin Rheumatol       Date:  2017-07-19       Impact factor: 2.980

10.  Successful treatment of resistant SAPHO syndrome with anti-TNF therapy.

Authors:  Shayma Lamya Hampton; Hazem Youssef
Journal:  BMJ Case Rep       Date:  2013-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.